The report “Pricing and Reimbursement in India- Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure” closely scrutinizes the major changes in pharmaceuticals related pricing and reimbursement in the recent past, and the impact these changes will have in the future. The health insurance is responsible for facilitating demand by making high-cost prescription drugs more affordable. Although the per capita income is rising in India, the modest income of most of the population keeps the high cost drugs and medicines out of reach of the majority of the population. Drugs would become more expensive with the enforcement of product patents and so the sales of the expensive drugs depend on the growth and the maturity of the health insurance sector. If the health insurance industry does not mature, the market for patented drugs would experience adverse effects. The next three to five years will see a significant growth and change in the Indian health insurance industry as new insurance players and insurance products respond to the increased demand. India has a dual system of care: a private fee-for-service based sector where the money is paid Out-Of-Pocket (OOP) by individual households and a tax-based public sector where the providers are salaried. The utilization of insurance under both these systems is partly restricted by the affordability of the individual household and availability of the budget. On the other hand, insurance, as a means of financing, is a far more sophisticated mechanism, requiring a comprehensive understanding of the failures that characterize health insurance markets.
- Detailed study of the healthcare systems and roles of the key insurance players in the drug reimbursement process
- Analysis of the major pricing and reimbursement mechanisms in India.
- Key trends that follow from the recent changes brought about in the pricing and reimbursement mechanism.
- Build an understanding of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in India.
Published: March 2012
Reasons to Buy
Price: Single User License: US$ 3500 Corporate User License: US$ 10500
Reasons to Buy
- Build understanding of the pharmaceuticals related key pricing and reimbursement mechanisms in India and also specifically in some states of India.
- Optimize your investment through the identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the Indian economy.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene of India.
- Improve negotiations with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Pricing and Reimbursement in the US – Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs
- Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
- Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues
- Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market